Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.39 |
| ▸ | RAB9A | P51151 | 7/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2135751 | 0.89 | ABL1 (0.43) | NPC1RAB9ASMN1; SMN2KDM4ETP53 | |
| SCHEMBL2134001 | 0.88 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2KDM4ETP53 | |
| SCHEMBL2135031 | 0.86 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2KDM4ETP53 | |
| SCHEMBL2139061 | 0.85 | ABL1 (0.48) | NPC1RAB9ASMN1; SMN2KDM4ETP53 | |
| SCHEMBL2135866 | 0.85 | SMN1; SMN2 (0.41) | NPC1RAB9ASMN1; SMN2KDM4ETP53 | |
| SCHEMBL2133800 | 0.85 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2KDM4ETP53 | |
| SCHEMBL2133207 | 0.83 | NPC1 (0.38) | NPC1RAB9ASMN1; SMN2KDM4ETP53 | |
| SCHEMBL2138344 | 0.83 | MTOR (0.41) | NPC1RAB9ASMN1; SMN2KDM4ETP53 | |
| SCHEMBL2135220 | 0.83 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2KDM4ETP53 | |
| SCHEMBL2135025 | 0.83 | MTOR (0.43) | NPC1RAB9ASMN1; SMN2KDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | NPC1 289/4885RAB9A 2165/4885SMN1; SMN2 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.